- A ubiquitin-conjugating enzyme (E2 enzyme) is the second key component of the ubiquitination cascade, functioning between the ubiquitin-activating enzyme (E1) and the ubiquitin ligase (E3).
- Once ubiquitin is activated by the E1 enzyme and linked through a thioester bond to E1’s active-site cysteine, it is transferred to the active-site cysteine of the E2 enzyme. This transfer generates an E2–ubiquitin conjugate, which is the intermediate step necessary for subsequent substrate modification. In this way, E2 enzymes act as crucial “carriers” of activated ubiquitin, bridging the initiation and substrate-targeting phases of ubiquitination.
- E2 enzymes are structurally defined by a conserved ubiquitin-conjugating (UBC) domain, approximately 150 amino acids long, which contains the catalytic cysteine residue that forms the thioester bond with ubiquitin. While most of the core structure is conserved, many E2 enzymes also possess N- or C-terminal extensions that confer specialized regulatory or interaction functions. This modular design enables the E2 family to participate in a wide variety of cellular processes while maintaining a conserved catalytic mechanism.
- Functionally, E2 enzymes play a critical role in determining the type of ubiquitin modification that is applied to a substrate. Depending on which E2 interacts with a given E3 ligase, the outcome may be monoubiquitination (single ubiquitin addition) or polyubiquitination (formation of a ubiquitin chain). Importantly, different chain topologies (e.g., K48-linked vs. K63-linked chains) encode different biological signals: K48 chains usually target proteins for proteasomal degradation, whereas K63 chains regulate signaling pathways, DNA repair, and trafficking. Thus, the choice of E2–E3 pairing is a major determinant of ubiquitination outcome.
- Humans have about 35 functional E2 enzymes, and their diversity allows the ubiquitin system to achieve high specificity and versatility. Each E2 has selective interactions with subsets of E3 ligases, creating a network of pairings that direct ubiquitination to thousands of potential substrates. For example, UBE2A and UBE2B (also known as RAD6A and RAD6B) are involved in DNA repair and cell cycle regulation, while UBE2D family members have broader substrate ranges and are commonly used by multiple E3s. Specialized E2s, such as UBE2I, work with ubiquitin-like proteins (e.g., SUMO) rather than ubiquitin itself.
- Disruption of E2 enzyme function has been linked to human disease. Mutations in UBE2A cause X-linked intellectual disability with developmental delay, seizures, and dysmorphic features, reflecting the enzyme’s critical role in neuronal protein regulation. Other E2s are implicated in cancer biology, where altered ubiquitination contributes to uncontrolled cell growth by affecting tumor suppressors and oncogenes. Because of their position at the heart of ubiquitination, E2 enzymes are increasingly studied as potential therapeutic targets in neurodevelopmental disorders, cancer, and immune dysregulation.
- In summary, ubiquitin-conjugating enzymes (E2s) are essential mediators of protein modification, transferring activated ubiquitin from E1 to E3 ligases and shaping the type and outcome of ubiquitin signaling. Their structural conservation, functional diversity, and disease relevance highlight their importance in maintaining cellular homeostasis and their potential as targets for therapeutic intervention.
Reliability Index *****
Note: If you notice any errors or inconsistencies, we welcome your feedback. Please share your observations in the comment box below — your input helps us improve.
Highest reliability: *****
Lowest reliability: *****
